Neurological Complications With Acute Sphenoid Sinusitis a Surgical Emergency?
Neurocrit Care 7:169-171, Poulopoulos,M. &Finelli,P.F., 2007
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke with Large-Vessel Occlusion
JAMA Neurol 79:22-31, Nguyen, T.N.,et al, 2022
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Hematopoietic Stem - and Progenitor-Cell Gene Therapy for Hurler Syndrome
NEJM 385:1929-1940, Gentner, B.,et al, 2021
Thrombolysis for Acute Ischemic Stroke in the Unwitnessed or Extended Therapeutic Time Window
Neurol 94:e1241-e1248, Tsivgoulis, G.,et al, 2020
Intravenous Alteplase for Stroke with Unknown Time of Onset Guided by Advanced Imaging:Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 396:1574-1585, Thomalla,G.,et al, 2020
Multimodal CT or MRI for IV thrombolysis in ischemic stroke with unknown time of onset
Neurol 95:e2954-e2964, Macha, K.,et al, 2020
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
NEJM 378:11-22,81, Nogueira, R.G.,et al, 2018
Development of High Signal Intensity within the Globus Pallidus and Dentate Nucleus following Multiple Adminstrations of Gadobenate Dimeglumine
AJNR 39:415-420, Bolles, G.M.,et al, 2018
High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted MR Images: Comparison between Gadobutrol and Linear Gadolinium-Based Contrast Agents
AJNR 39:421-426, Moser, F.G.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Introduction of a Dedicated Emergency Department MR Imaging Scanner at the Barrow Neurological Institute
AJNR 38:1480-1485, Buller, M. & Karis, JP, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Ann Neurol 81:849-856, Lansberg, M.G.,et al, 2017
Favorable Bridging Therapy Based on DWI-FLAIR Mismatch in Patients with Unclear-Onset Stroke
AJNR 37:88-93, Mourand, I.,et al, 2016
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
Use of MRI in the Diagnosis of Fetal Brain Abnormalities in Utero (MERIDIAN): A Multicentre, Prospective Cohort Study
, Griffiths, P.D.,et al, 2016
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Microbleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients with Acute Ischemic Stroke
Stroke 46:2458-2463,2403, Turc, G.,et al, 2015
Multimodal Diagnostic Imaging for Hyperacute Stroke
AJNR 36:2206-2213, Vo, K.D.,et al, 2015
Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014
Preexisting Cerebral Microbleeds on Susceptibility-Weighted Magnetic Resonance Imaging and Post-Thrombolysis Bleeding Risk in 392 Patients
Stroke 45:1684-1688, Gratz, P.P.,et al, 2014
Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014
CD49d Antisense Drug ATL1102 Reduces Disease Activity in Patients with Relapsing-Remitting MS
Neurol 83:1780-1788, Limmroth, V.,et al, 2014
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 379:322-34, Heneghan,C., 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Prevalence of MRI-defined recent silent ischemia and associated bleeding risk with thrombolysis
Neurol 76:1288-1295, Tisserand, M.,et al, 2011
Efficacy and Safety of Combination Antiplatelet Therapies in Patients with Symptomatic Intracranial Atherosclerotic Stenosis
Stroke 42:2883-2890, Kwon, S.U.,et al, 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison With Double-Dose Gadopentetate Dimeglumine
AJNR 31:1055-1058, Kim,E.S., et al, 2010
Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009